|
NL188581C
(nl)
*
|
1974-07-15 |
1992-08-03 |
Akzo Nv |
Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
|
|
ZA763131B
(en)
*
|
1975-05-27 |
1978-01-25 |
Syntex Inc |
Use of flunisolide to treat respiratory diseases
|
|
SE8008524L
(sv)
*
|
1980-12-04 |
1982-06-05 |
Draco Ab |
4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
|
|
IT1196142B
(it)
*
|
1984-06-11 |
1988-11-10 |
Sicor Spa |
Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
|
|
SE8604059D0
(sv)
*
|
1986-09-25 |
1986-09-25 |
Astra Pharma Prod |
A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
|
|
GR1001529B
(el)
*
|
1990-09-07 |
1994-03-31 |
Elmuquimica Farm Sl |
Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
|
|
SE9100341D0
(sv)
*
|
1991-02-04 |
1991-02-04 |
Astra Ab |
Novel steroids
|
|
ATE183192T1
(de)
*
|
1993-01-08 |
1999-08-15 |
Astra Ab |
Neue colon-oder ilean-spezifische steroid derivate
|
|
DE19635498A1
(de)
*
|
1996-09-03 |
1998-03-26 |
Byk Gulden Lomberg Chem Fab |
Verfahren zur Epimerenanreicherung
|
|
IT1291288B1
(it)
|
1997-04-30 |
1999-01-07 |
Farmabios Srl |
Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
|
|
US6266556B1
(en)
|
1998-04-27 |
2001-07-24 |
Beth Israel Deaconess Medical Center, Inc. |
Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
|
|
IL144900A
(en)
|
2001-08-14 |
2013-12-31 |
Neurim Pharma 1991 |
Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
|
|
US7825147B2
(en)
*
|
2003-08-29 |
2010-11-02 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type-IV
|
|
US20070259874A1
(en)
*
|
2003-11-26 |
2007-11-08 |
Palle Venkata P |
Phosphodiesterase Inhibitors
|
|
CN1942470A
(zh)
|
2004-04-09 |
2007-04-04 |
默克公司 |
Akt活性抑制剂
|
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
|
US7915286B2
(en)
|
2005-09-16 |
2011-03-29 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
|
CA2626628A1
(en)
*
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type iv inhibitors
|
|
WO2007045979A1
(en)
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions of muscarinic receptor antagonists
|
|
MX2009003100A
(es)
*
|
2006-09-22 |
2009-05-11 |
Ranbaxy Lab Ltd |
Inhibidores de fosfodiesterasa tipo iv.
|
|
US20100029728A1
(en)
*
|
2006-09-22 |
2010-02-04 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
PT2099442E
(pt)
|
2006-12-26 |
2015-02-10 |
Pharmacyclics Inc |
Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
|
|
EA016079B1
(ru)
|
2007-01-10 |
2012-01-30 |
Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа |
Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
|
|
US20080207659A1
(en)
*
|
2007-02-15 |
2008-08-28 |
Asit Kumar Chakraborti |
Inhibitors of phosphodiesterase type 4
|
|
PT2124944E
(pt)
*
|
2007-03-14 |
2012-05-17 |
Ranbaxy Lab Ltd |
Derivados de pirazolo[3,4-b]piridina como inibidores de fosfodiesterase
|
|
US20110130403A1
(en)
*
|
2007-03-14 |
2011-06-02 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
|
|
AU2008269154B2
(en)
|
2007-06-27 |
2014-06-12 |
Merck Sharp & Dohme Llc |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
ITMI20080645A1
(it)
|
2008-04-11 |
2009-10-12 |
Ind Chimica Srl |
Procedimento per la preparazione di budesonide
|
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
|
GB0900484D0
(en)
|
2009-01-13 |
2009-02-11 |
Angeletti P Ist Richerche Bio |
Therapeutic agent
|
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
|
EP2993178A1
(en)
*
|
2009-09-11 |
2016-03-09 |
CHIESI FARMACEUTICI S.p.A. |
Glucocorticoid condensed in position 16,17 with an isoxazolidine group
|
|
GB0916608D0
(en)
|
2009-09-22 |
2009-11-04 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
JP5099731B1
(ja)
|
2009-10-14 |
2012-12-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ｐ５３活性を増大する置換ピペリジン及びその使用
|
|
JP2013518909A
(ja)
|
2010-02-08 |
2013-05-23 |
キナゲン，インク． |
アロステリックキナーゼ阻害が関係する治療方法および組成物
|
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
AU2011285909B2
(en)
|
2010-08-02 |
2016-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
|
EP2606134B1
(en)
|
2010-08-17 |
2019-04-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
EP2699567A1
(en)
|
2011-04-21 |
2014-02-26 |
Merck Sharp & Dohme Corp. |
Insulin-like growth factor-1 receptor inhibitors
|
|
NZ621221A
(en)
|
2011-09-13 |
2016-07-29 |
Pharmacyclics Llc |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
EP3358013B1
(en)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
US9018380B2
(en)
|
2012-08-24 |
2015-04-28 |
Boar of Regents, The University of Texas System |
Heterocyclic modulators of HIF activity for treatment of disease
|
|
US9155747B2
(en)
*
|
2012-09-13 |
2015-10-13 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
|
KR20150060724A
(ko)
|
2012-09-28 |
2015-06-03 |
머크 샤프 앤드 돔 코포레이션 |
Erk 억제제인 신규 화합물
|
|
DK2925888T3
(en)
|
2012-11-28 |
2017-12-18 |
Merck Sharp & Dohme |
COMPOSITIONS AND METHODS OF CANCER TREATMENT
|
|
EP2935263B1
(en)
|
2012-12-20 |
2018-12-05 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
WO2017222951A1
(en)
|
2016-06-23 |
2017-12-28 |
Merck Sharp & Dohme Corp. |
3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
|
|
WO2018071283A1
(en)
|
2016-10-12 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Kdm5 inhibitors
|
|
KR20250114431A
(ko)
|
2016-11-08 |
2025-07-29 |
리제너론 파마슈티칼스 인코포레이티드 |
스테로이드 및 이의 단백질-접합체
|
|
KR20200007905A
(ko)
|
2017-05-18 |
2020-01-22 |
리제너론 파마슈티칼스 인코포레이티드 |
사이클로덱스트린 단백질 약물 접합체
|
|
IL313068A
(en)
|
2017-11-07 |
2024-07-01 |
Regeneron Pharma |
Hydrophilic linkers for antibody drug conjugates
|
|
US11098059B2
(en)
|
2017-11-08 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
IL275757B2
(en)
|
2018-01-08 |
2025-08-01 |
Regeneron Pharma |
Steroids and antibody-conjugates thereof
|
|
MX2020011546A
(es)
|
2018-05-09 |
2021-01-29 |
Regeneron Pharma |
Anticuerpos anti-msr1 y metodos de uso de los mismos.
|
|
EP3833668B1
(en)
|
2018-08-07 |
2025-03-19 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
WO2020033285A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
BR112021002267A8
(pt)
|
2018-08-07 |
2023-02-07 |
Merck Sharp & Dohme |
Inibidores de prmt5
|
|
EP4076460B1
(en)
|
2019-12-17 |
2026-01-21 |
Merck Sharp & Dohme LLC |
1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
|
|
EP4076459B1
(en)
|
2019-12-17 |
2026-04-29 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
CA3160153A1
(en)
|
2019-12-17 |
2021-06-24 |
Michelle Machacek |
Prmt5 inhibitors
|
|
BR112022012015A2
(pt)
|
2019-12-17 |
2022-08-30 |
Merck Sharp & Dohme Llc |
Inibidores de prmt5
|
|
KR20250053961A
(ko)
|
2022-09-02 |
2025-04-22 |
머크 샤프 앤드 돔 엘엘씨 |
엑사테칸-유래 토포이소머라제-1 억제제 제약 조성물 및 그의 용도
|
|
TW202432099A
(zh)
|
2022-10-25 |
2024-08-16 |
美商默沙東有限責任公司 |
源自依克沙替康(exatecan)之adc連接子-載藥(payload)、醫藥組合物及其用途
|
|
IL321395A
(en)
|
2022-12-14 |
2025-08-01 |
Merck Sharp & Dohme Llc |
Auristatin cargo-linkers, pharmaceutical compounds, and their uses
|